OncLive® On Air

S9 Ep29: Garcia-Manero and Zeidan Highlight Key Implications of the COMMANDS Trial in Lower-Risk MDS

28 Sep 2023

Contributed by Lukas

Drs Garcia-Manero and Zeidan discuss the significance of efficacy and safety data from the COMMANDS trial in MDS, takeaways from the subgroup analyses...

S9 Ep28: FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

21 Sep 2023

Contributed by Lukas

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispe...

S9 Ep27: Jones and Somaiah Review the Rationale and Design of the Peak Trial in GIST

18 Sep 2023

Contributed by Lukas

Drs Jones and Somaiah discuss unmet needs in GIST that the Peak trial seeks to answer; the advantages of the methods and design of this trial; and how...

S9 Ep26: Chuong Discusses the Importance of MRI-Guided Radiotherapy in Cancer

14 Sep 2023

Contributed by Lukas

Dr Chuong discusses the evolution of MRI-guided radiation in the cancer treatment armamentarium, the benefits of the MRIdian SMART system, and how Mia...

S9 Ep25: Fonkoua Sheds Light on Liver Cancer Clinical Trial Disparities

11 Sep 2023

Contributed by Lukas

Dr Fonkoua discusses the ways in which common clinical trial enrollment criteria in oncology exclude patients from underrepresented groups, enrollment...

S9 Ep24: FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma

07 Sep 2023

Contributed by Lukas

Dr Minnema discusses the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma, key data from the MonumenTAL-1 trial, and ...

S9 Ep23: Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

04 Sep 2023

Contributed by Lukas

Dr Usmani discusses the integration of elranatamab, talquetamab, and telcistamab into the management of relapsed/refractory multiple myeloma, common a...

S9 Ep22: Kelley Discusses Efficacy and Safety Considerations With the STRIDE Regimen in HCC

31 Aug 2023

Contributed by Lukas

Dr Kelley discusses standard first-line treatment options for patients with advanced HCC, key findings from the phase 3 HIMALAYA trial, and the safety...

S9 Ep21: FDA Approval Insights: Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer

28 Aug 2023

Contributed by Lukas

Dr Mirza discusses the FDA approval of dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer; key...

S9 Ep20: FDA Approval Insights: Quizartinib in Newly Diagnosed, FLT3-ITD+ AML

21 Aug 2023

Contributed by Lukas

Dr Sekeres discusses the FDA approval of quizartinib plus chemotherapy in patients with newly diagnosed, FLT3-ITD–positive AML, key efficacy and saf...

S9 Ep19: Trent Breaks Down Mutation Testing and ctDNA Monitoring in GIST

17 Aug 2023

Contributed by Lukas

Dr Trent discusses the need for improved awareness around mutation testing in GIST, the limitations of current clinical trial criteria, and the potent...

S9 Ep18: Bhatnagar Spotlights Ongoing Uproleselan Investigations in AML

14 Aug 2023

Contributed by Lukas

Dr Bhatnagar discusses the prior and ongoing studies evaluating the addition of uproleselan to standard-of-care regimens for patients with AML, why up...

S9 Ep17: Sanai Spotlights Meningioma Symptoms, Treatment Options, and Research Needs

10 Aug 2023

Contributed by Lukas

Dr Sanai discusses the prevalence and grading of malignant meningiomas; common symptoms associated with these tumors; treatment modalities for high-gr...

S9 Ep16: Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers

07 Aug 2023

Contributed by Lukas

Dr Danish discusses barriers to using radiotherapy for the treatment of patients with metastatic lung and bone cancers; the novel capabilities of SCIN...

S9 Ep15: FDA Approval Insights: Glofitamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

03 Aug 2023

Contributed by Lukas

Dr Carlo-Stella discusses the FDA approval of glofitamab in relapsed/refractory DLBCL, key efficacy and safety findings from the NP30179 trial, and th...

S9 Ep14: Trent Talks Through Potential Clinical Applications and Future Directions for MRD in GIST

31 Jul 2023

Contributed by Lukas

Dr Trent discusses the current role and significance of using MRD in gastrointestinal stromal tumor, current guidelines around mutation testing, and r...

S9 Ep13: Lunning and Kamdar Debate the Role of Pola-R-CHP in Treatment-Naïve DLBCL

24 Jul 2023

Contributed by Lukas

Dr Lunning sits down with Manali Kamdar, MD, of the University of Colorado, to discuss the design of the POLARIX trial, the ways in which its results ...

S9 Ep12: Khan and Kwendakwema Discuss Financial Toxicity in Patients With Cancer

20 Jul 2023

Contributed by Lukas

Drs Khan and Kwendakwema discuss the methods and design of two studies investigating adverse financial events in patients with cancer, the future impl...

S9 Ep11: FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

17 Jul 2023

Contributed by Lukas

Dr Agarwal discusses the significance of the FDA approval of talazoparib plus enzalutamide in HRR gene–mutated mCRPC, key efficacy and safety data f...

S9 Ep10: Lunning and Abramson Spotlight Developments and Challenges in LBCL Research and Management

13 Jul 2023

Contributed by Lukas

Dr Lunning sits down with Jeremy Abramson, MD, of Massachusetts General Hospital, to discuss treatment options for patients with LBCL following relaps...

S9 Ep9: FDA Approval Insights: Avapritinib in Indolent Systemic Mastocytosis

10 Jul 2023

Contributed by Lukas

Dr Gotlib discusses the significance of the FDA approval of avapritinib in indolent systemic mastocytosis, key findings from the PIONEER trial, and th...

S9 Ep8: King Describes Unmet Needs and the Role of Surgical Resection in Residual Non-RP Testicular Cancer

06 Jul 2023

Contributed by Lukas

Dr King discusses the need for improved guidance when determining the appropriate management strategy for patients with residual nonretroperitoneal te...

S9 Ep7: Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis

03 Jul 2023

Contributed by Lukas

Dr Kremyanskaya discusses the results from cohort 1 of the MANIFEST trial in treatment-naïve myelofibrosis, differentiating features of pelabresib an...

S9 Ep6: Short Shares Post-Conference Perspectives in Acute Lymphoblastic Leukemia From ASCO and EHA 2023

29 Jun 2023

Contributed by Lukas

Dr Short discusses data in acute lymphoblastic leukemia that were presented at the 2023 ASCO Annual Meeting and EHA Congress.

S9 Ep5: Manana Discusses Systemic Racism in Oncology and Future Steps for Equitable Cancer Care

22 Jun 2023

Contributed by Lukas

Dr Manana discusses how systemic racism appears in oncology practice, tools clinicians can use to learn about and address their implicit biases, and t...

S9 Ep4: Reuss Reviews the Development of LP-300 in Advanced NSCLC

19 Jun 2023

Contributed by Lukas

Dr Reuss discusses the development of LP-300 in advanced NSCLC, the mechanisms of LP-300 that may help synergize with the activity of platinum-based c...

S9 Ep3: FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

15 Jun 2023

Contributed by Lukas

Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel...

S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

12 Jun 2023

Contributed by Lukas

Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-...

S9 Ep1: Holowatyj Highlights Challenges and Opportunities in Appendix Cancer Research

08 Jun 2023

Contributed by Lukas

Dr Holowatyj discusses symptoms associated with appendix cancer, challenges related to understanding the incidence and risk factors of this disease, a...

S8 Ep50: Raskin Reflects on the Career-Long Role of Fellowship and Education in Orthopaedic Oncology

05 Jun 2023

Contributed by Lukas

Dr Raskin discusses the road from fellow to fellowship director at Massachusetts General Hospital, the importance of transparency in a program amid in...

S8 Ep49: Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML

29 May 2023

Contributed by Lukas

Dr Andreeff discusses the evaluation of uproleselan for the treatment of patients with acute myeloid leukemia, the rationale for targeting E-selectin ...

S8 Ep48: Gottschalk and Krenciute Discuss the Development of CAR T-cell Therapy in Pediatric Solid Tumors 

25 May 2023

Contributed by Lukas

Drs Gottschalk and Krenciute discuss the difficulties of translating successes with CAR T-cell therapy in adults to the pediatric population; ongoing ...

S8 Ep47: Mutale Discusses Disparities in Cancer Clinical Trial Eligibility, Access and Enrollment

22 May 2023

Contributed by Lukas

Dr Mutale discusses common factors contributing to decreased access to cancer clinical trials, how trial enrollment criteria can affect which groups o...

S8 Ep46: Oncology Professionals Explain the Nuances of Career-Building Mentorship and Self-Advocacy

18 May 2023

Contributed by Lukas

Drs Kovacic, Shaughnessy, Starnes, and Waltz highlight the differences in work culture from their early careers to now, gender-related challenges that...

S8 Ep45: FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

15 May 2023

Contributed by Lukas

Dr Horwitz discusses the FDA approval of omidubicel in patients with blood cancers, key efficacy and safety data from the pivotal phase 3 trial, and t...

S8 Ep44: Haffner Highlights Treatment and Research Considerations for Basal Cell Carcinoma of the Prostate

11 May 2023

Contributed by Lukas

Dr Haffner explains distinguishing features between basal cell and adenocarcinoma of the prostate, findings from a genomics study of basal cell prosta...

S8 Ep43: Ehrhardt Explains the Effects of Modifiable Health Conditions on Late Mortality for Childhood Cancer Survivors

08 May 2023

Contributed by Lukas

Dr Ehrhardt discusses how modifiable chronic health conditions may relate to social determinants of health, noting how these factors can potentially l...

S8 Ep41: Stand Up to Cancer Grant Recipients Discuss Initiative to Expand Access to Early-Phase Clinical Trials

01 May 2023

Contributed by Lukas

Faculty across 4 institutions discuss their participation in a 4-team initiative launched by Stand Up To Cancer® that focuses on expanding access to ...

S8 Ep40: Kim Discusses the Development of LP-300 Plus Chemotherapy in Advanced Lung Cancer

27 Apr 2023

Contributed by Lukas

Dr Kim discusses the evaluation of LP-300 for the treatment of patients with advanced lung adenocarcinoma, the rationale for exploring this agent in c...

S8 Ep39: FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

24 Apr 2023

Contributed by Lukas

Dr Friedlander discusses the FDA approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial carcinom...

S8 Ep38: Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

20 Apr 2023

Contributed by Lukas

Drs Gushchin and Diaz-Montes discuss findings from the HOT trial evaluating health-related QOL outcomes after cytoreductive surgery and HIPEC in patie...

S8 Ep37: Desai Discusses the Significance of a Supportive, Foundational Fellowship Experience

17 Apr 2023

Contributed by Lukas

Dr Desai discusses the aspects of his oncology fellowship experience that have had the greatest influence on his career growth, the role of mentorship...

S8 Ep36: FDA Approval Insights: Dostarlimab in dMMR Advanced Endometrial Cancer

13 Apr 2023

Contributed by Lukas

Dr Gilbert discusses the FDA approval of dostarlimab in patients with endometrial cancer, key efficacy data from the GARNET trial, and how this agent ...

S8 Ep35: Gynecologic Cancer Experts Review 2023 SGO Research and Treatment Updates

10 Apr 2023

Contributed by Lukas

Presenters from the 2023 SGO Annual Meeting share their insights on the treatment of patients with gynecologic cancers.

S8 Ep34: Mercado and Kovacs Emphasize the Importance of Multidisciplinary Lung Cancer Screening and Management

06 Apr 2023

Contributed by Lukas

Drs Mercado and Kovacs discuss the importance of multidisciplinary approaches to lung cancer screening and management, barriers to lung cancer screeni...

S8 Ep33: Kishan Discusses GI Toxicity Reduction With MRI-Guided SBRT in Prostate Cancer

03 Apr 2023

Contributed by Lukas

Dr Kishan discusses the use of MRI-guided SBRT in prostate cancer to reduce acute genitourinary and gastrointestinal toxicity; findings from the MIRAG...

S8 Ep32: FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

30 Mar 2023

Contributed by Lukas

Dr Bidard discusses the FDA approval of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, ke...

S8 Ep31: Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

27 Mar 2023

Contributed by Lukas

Faculty from the 40th Annual Miami Breast Cancer Conference® feature updates in the treatment of patients across the breast cancer continuum.

S8 Ep29: FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer

20 Mar 2023

Contributed by Lukas

Dr Tolaney discusses the FDA approval of sacituzumab govitecan in patients with unresectable locally advanced or metastatic HR-positive, HER2-negative...

S8 Ep28: Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC

16 Mar 2023

Contributed by Lukas

Dr Raez discusses findings from a study of patients with newly diagnosed non–small cell lung cancer who received both liquid and tissue biopsy, the ...

S8 Ep27: Milner, Dalal, and Ligon Discuss Stem Cell Transplant Methods, Results, and Risk Factors in Pediatric Patients

13 Mar 2023

Contributed by Lukas

Drs Milner, Dalal, and Ligon discuss hematopoietic stem cell transplant in children with severe aplastic anemia, graft failure risk factors in childre...

S8 Ep26: FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC

09 Mar 2023

Contributed by Lukas

Dr Herbst discusses the FDA approval of adjuvant pembrolizumab in non–small cell lung cancer, key efficacy and safety data from the KEYNOTE-091 tria...

S8 Ep25: CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

06 Mar 2023

Contributed by Lukas

Drs Khushalani, Dietrich, Luke, and Patel discuss the nuances of defining resectability in cutaneous squamous cell carcinoma, the evolving treatment p...

S8 Ep24: Jakubowiak Highlights PFS Benefit Seen With KRd Maintenance in Newly Diagnosed Multiple Myeloma

02 Mar 2023

Contributed by Lukas

Dr Jakubowiak discusses interim findings from the ATLAS trial of KRd vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma, co...

S8 Ep23: FDA Approval Insights: Pirtobrutinib in MCL

27 Feb 2023

Contributed by Lukas

Dr Leslie discusses the FDA approval of pirtobrutinib in patients with MCL previously treated with a BTK inhibitor, key efficacy and safety findings f...

S8 Ep22: Mascarenhas Summarizes Therapeutic Standards and Advances in Myelofibrosis Management

23 Feb 2023

Contributed by Lukas

Dr Mascarenhas discusses established standards of care and ongoing research with JAK inhibitors in patients with myelofibrosis; the available frontlin...

S8 Ep21: FDA Approval Insights: Zanubrutinib in CLL and SLL

16 Feb 2023

Contributed by Lukas

Drs Flinn, Lamanna, Brown, and Tam discuss the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.

S8 Ep20: Small and Reagan Review Tumor Lysis Syndrome Risk Factors and Management Strategies

13 Feb 2023

Contributed by Lukas

Drs Short and Reagan discuss risk factors that can contribute to patients’ likelihood of developing tumor lysis syndrome, preventive measures for pa...

S8 Ep19: D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

09 Feb 2023

Contributed by Lukas

Dr D’Amato discusses research in sarcoma and gastrointestinal stromal tumor, incorporating circulating tumor DNA analysis into routine reevaluation ...

S8 Ep19: FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

06 Feb 2023

Contributed by Lukas

Dr Strickler discusses the FDA approval of tucatinib plus trastuzumab in metastatic colorectal cancer, key efficacy and safety findings from the MOUNT...

S8 Ep18: Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma

02 Feb 2023

Contributed by Lukas

Dr Rosenthal discusses the care of adolescent and young adult patients with Hodgkin lymphoma, the discrepancies between pediatric and adult oncologist...

S8 Ep17: Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer

30 Jan 2023

Contributed by Lukas

Dr Nair discusses a study evaluating the role of yoga as a complementary therapy in patients with breast cancer, how these results emphasize the impor...

S8 Ep17: FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

26 Jan 2023

Contributed by Lukas

Dr Shore discusses the FDA approval of nadofaragene firadenovec in non–muscle invasive bladder cancer, the benefits of this therapy’s administrati...

S8 Ep16: Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer 

23 Jan 2023

Contributed by Lukas

Drs Goetz and Choong discuss the potential for adjuvant endocrine therapy omission in patients with estrogen receptor–positive breast cancer who hav...

S8 Ep15: Dy Discusses CEACAM5-Directed and Other Second-Line Treatment Strategies in NSCLC

19 Jan 2023

Contributed by Lukas

Dr Dy discusses the development of CEACAM5-directed antibody-drug conjugates in non–small cell lung cancer, ongoing research with tusamitamab ravtan...

S8 Ep14: Giacchetti Discusses the Convergence of Chronobiology and Oncologic Care in Breast Cancer

16 Jan 2023

Contributed by Lukas

Dr Giacchetti discusses the findings from a study of patient-selected timing of the daily oral intake of adjuvant hormone therapy and everolimus in br...

S8 Ep14: Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

12 Jan 2023

Contributed by Lukas

Dr Hilal discusses data with frontline ibrutinib, acalabrutinib, and zanubrutinib in chronic lymphocytic leukemia; remaining uncertainties regarding t...

S8 Ep12: Breast Cancer Experts Review HR+ Treatment Updates From SABCS 2022

05 Jan 2023

Contributed by Lukas

Drs Lu, Neven, Jacot, Medford, and Spring highlight updates in the treatment of hormone receptor–positive breast cancer that were presented at the 2...

S8 Ep11: Oppong Emphasizes How Patient Education Can Lower Breast Cancer Surgery Refusal Rates

02 Jan 2023

Contributed by Lukas

Dr Oppong discusses findings showing that Black and Hispanic women are more likely than their White counterparts to refuse surgery for nonmetastatic b...

S8 Ep10: Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors

29 Dec 2022

Contributed by Lukas

Dr Somaiah discusses the excitement surrounding novel agents such as CSF1R inhibitors and ULK1/2 inhibitors, and the utility of broad spectrum TKIs su...

S8 Ep9: Rugo Summarizes Developments With Ribociclib and ADCs in HR-Positive Breast Cancer

26 Dec 2022

Contributed by Lukas

Dr Rugo discusses the second interim analysis of overall survival in the TROPiCS-02 trial, the implications of post-progression treatments after riboc...

S8 Ep8: Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment

22 Dec 2022

Contributed by Lukas

Dr Kumar, Dr Patel, Falbo, and Ahlstrom highlight the importance of community-based discussions regarding adverse effects in multiple myeloma, the ben...

S8 Ep7: Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma

19 Dec 2022

Contributed by Lukas

Dr Blum discusses renal medullary carcinoma, the lack of approved systemic therapy for these patients, and findings showing a correlation between CA-1...

S8 Ep6: FDA Approval Insights: Tremelimumab Plus Durvalumab and Chemotherapy in NSCLC

15 Dec 2022

Contributed by Lukas

Dr Johnson discusses the FDA approval of tremelimumab plus durvalumab and chemotherapy in non–small cell lung cancer, key data from the POSEIDON tri...

S8 Ep5: Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent

12 Dec 2022

Contributed by Lukas

Nicholas Acuna discusses research showing that incidence of liver cancer increases over time in people of Mexican descent living in Los Angeles, the “...

S8 Ep4: Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

08 Dec 2022

Contributed by Lukas

Dr Brody previews mantle cell lymphoma data being presented at the 2022 ASH Annual Meeting and Exposition, including promising data on pirtobrutinib f...

S8 Ep3: FDA Approval Insights: Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

05 Dec 2022

Contributed by Lukas

Dr Matulonis discusses the FDA approval of mirvetuximab soravtansine-gynx in folate receptor alpha–positive, platinum-resistant ovarian cancer, key ...

S8 Ep2: Leone Lays Out Research Needs and Treatment Approaches in Male Breast Cancer

01 Dec 2022

Contributed by Lukas

Dr Leone discusses the distinguishing features of male breast cancer, the benefits and limitations of current treatments, and the importance of raisin...

S8 Ep1: Florez Discusses Crucial Aspects of Cancer Care Equity and Survivorship

28 Nov 2022

Contributed by Lukas

Dr Florez discusses why cancer care equity and survivorship should be a priority for all physicians, the steps the health care system needs to take to...

S7 Ep50: FDA Approval Insights: Durvalumab Plus Tremelimumab in HCC

24 Nov 2022

Contributed by Lukas

Dr Abou-Alfa discusses the FDA approval of durvalumab plus tremelimumab in unresectable hepatocellular carcinoma, the regimen’s unique mechanism of ...

S7 Ep49: Crane Helps Gynecologic Fellows Deliver Care in a Complicated Time

21 Nov 2022

Contributed by Lukas

Dr Crane discusses why Atrium Health decided to launch a gyn onc fellowship, how she helps fellows navigate the current political landscape while main...

S7 Ep48: Oppong Sheds Light on Racial Disparities in Breast Cancer Diagnosis and Mortality

17 Nov 2022

Contributed by Lukas

Dr Oppong discusses factors that contribute to the ongoing disparity in breast cancer deaths among Black women vs White women, the importance of incre...

S7 Ep47: FDA Approval Insights: Teclistamab in Relapsed/Refractory Multiple Myeloma

14 Nov 2022

Contributed by Lukas

Dr Garfall discusses the FDA approval of teclistamab in relapsed/refractory multiple myeloma, key efficacy and safety data from the MajesTEC-1 trial, ...

S7 Ep46: Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022

10 Nov 2022

Contributed by Lukas

In this inaugural episode, Dr Lunning details important findings to come out of the Pan Pacific Lymphoma Conference, including results evaluating prop...

S7 Ep45: Sauter and Hill Talk Through CAR T Cell Sequencing and Access in Lymphomas

07 Nov 2022

Contributed by Lukas

Drs Sauter and Hill discuss the use of CAR T-cell therapy in patients with lymphomas, the potential for allogeneic CAR T cells, and ways to expand acc...

S7 Ep44: FDA Approval Insights: Futibatinib in FGFR2-Positive Cholangiocarcinoma

03 Nov 2022

Contributed by Lukas

Dr Goyal discusses the FDA approval of futibatinib in FGFR2-positive cholangiocarcinoma, key safety data from the FOENIX*-CCA2 trial, and the importan...

S7 Ep43: Thymic Cancer Experts Discuss the Latest Data, Need for More Research Funding

31 Oct 2022

Contributed by Lukas

Drs Giaccone and He discuss the implications of their thymic cancer research, the importance of combining immunotherapy and anti-angiogenesis agents t...

S7 Ep42: Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care

27 Oct 2022

Contributed by Lukas

Drs Mikhael and Cole discuss ways to help reduce disparities in myeloma by delivering culturally relevant care and highlight the importance of impleme...

S7 Ep41: FDA Approval Insights: Sodium Thiosulfate in Cisplatin-Treated Pediatric Solid Tumors

24 Oct 2022

Contributed by Lukas

Dr Shah discusses the FDA approval of sodium thiosulfate in pediatric patients with solid tumors treated with cisplatin, key efficacy and safety data ...

S7 Ep40: Leukemia Experts Discuss Early Career Growth, Mentorship, and Gender Bias in Academia

20 Oct 2022

Contributed by Lukas

Drs DiNardo, Wang, and Altman discuss the challenges they faced in their early careers, the rollout of molecular profiling and targeted therapy in the...

S7 Ep39: Community Perspectives on Integrating and Interpreting Molecular Testing Results in NSCLC

17 Oct 2022

Contributed by Lukas

Drs Ramkumar and Morganstein discuss the challenges they face with integrating and organizing molecular testing results into electronic medical record...

S7 Ep38: FDA Approval Insights: Selpercatinib in RET Fusion–Positive Solid Tumors

13 Oct 2022

Contributed by Lukas

Dr Subbiah discusses the significance of the FDA approval of selpercatinib in RET fusion–positive non–small cell lung cancer, thyroid cancer, and ...

S7 Ep37: Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

10 Oct 2022

Contributed by Lukas

Dr Brentjens discusses targeting the “enigmatic” GPRC5D protein, safety results with MCARH109, and the appropriate sequencing for the agent.

S7 Ep36: Velcheti Discusses Mobile Telehealth-Based Research to Close Cancer Care Gaps

06 Oct 2022

Contributed by Lukas

Dr Velcheti discusses planned research into whether mobile technology services can improve patient outcomes for underserved and underrepresented patie...

S7 Ep35: FDA Approval Insights: Durvalumab Plus Gemcitabine and Cisplatin in Biliary Tract Cancer

03 Oct 2022

Contributed by Lukas

Dr Oh discusses the FDA approval of durvalumab plus gemcitabine and cisplatin in biliary tract cancer, the tolerability of the regimen, and the import...

S7 Ep34: Shepard Discusses Symptoms, Management, and Future Directions in Desmoid Tumors

29 Sep 2022

Contributed by Lukas

Dr Shepard discusses the unpredictable course of desmoid tumors, the use of TKIs for these tumors, and findings from 2 trials presented at the 2022 ES...

S7 Ep33: Deol on the Importance of a Well-Rounded Fellowship Experience

26 Sep 2022

Contributed by Lukas

Dr Deol discusses what he wants his trainees to take from the fellowship program he directs, how his colleagues help fellows find jobs, and how he hel...

S7 Ep32: Patel Provides Insight Into Post-Transplant Complications in Myeloid Disorders

22 Sep 2022

Contributed by Lukas

Dr Patel discusses post-transplant complications in myeloid disorders, the prevalence of these complications, and the most common ones that may arise,...

S7 Ep31: FDA Approval Insights: Pemigatinib in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms

19 Sep 2022

Contributed by Lukas

Dr Verstovsek discusses the FDA approval of pemigatinib in myeloid/lymphoid neoplasms with FGFR1 rearrangements, the transformative effects of pemigat...

S7 Ep30: Leal Sheds Light on Symptoms and Treatment of Lambert-Eaton Myasthenic Syndrome

15 Sep 2022

Contributed by Lukas

Dr Leal discusses the symptoms commonly associated with Lambert-Eaton Myasthenic Syndrome, the prevalence of this disorder in concurrence with underly...